This product is a CRISPR/Cas9-edited polyclonal knockout cell population targeting the GNPDA1 gene in the HeLa cell background. The polyclonal format comprises a heterogeneous pool of cells carrying diverse loss-of-function mutations at the GNPDA1 locus, generated by non-homologous end joining following Cas9-mediated DNA cleavage. This population-based model avoids clonal selection artifacts and provides a robust system for interrogating GNPDA1 function across a range of genetic disruption events. It is designed for researchers investigating hexosamine metabolism and its intersection with glycolysis and O-GlcNAcylation in a widely used cancer cell context.
HeLa is an immortalized epithelial cell line derived from a human cervical adenocarcinoma and is positive for human papillomavirus type 18 (HPV18). These cells exhibit an adherent growth pattern and have a transformed phenotype, making them a staple in cancer biology for studies on gene expression, drug toxicity, and signal transduction. The HeLa background offers a well-characterized platform with extensive literature support, enabling seamless integration of GNPDA1 knockout data into existing knowledge on oncogenic signaling and metabolic reprogramming.
GNPDA1 encodes glucosamine-6-phosphate deaminase 1, which catalyzes the hydrolytic deamination of glucosamine-6-phosphate to fructose-6-phosphate and ammonia. This enzymatic step links the aminosugar salvage pathway to glycolysis and the hexosamine biosynthetic pathway. GNPDA1 acts downstream of hexosamine pathway entry mediated by GFAT1 and is subject to regulation by upstream effectors including glucose, insulin, glucosamine-6-phosphate, O-GlcNAcylation feedback, and HIF-1??. Its reaction directly influences the UDP-GlcNAc pool, a substrate for OGT-mediated O-GlcNAcylation, and glycolytic flux. The enzyme interacts physically and functionally with GFAT1, GNPDA2, phosphoglucose isomerase, and hexokinase, forming a node that coordinates carbon and nitrogen metabolism.
In HeLa cells, which exhibit high basal glycolytic activity and active hexosamine pathway flux due to their transformed state and rapid proliferation, GNPDA1 knockout is expected to alter the balance between amino sugar utilization and energy production. Disruption of GNPDA1 may reduce conversion of exogenous glucosamine-6-phosphate to fructose-6-phosphate, potentially depleting glycolytic intermediates and lowering UDP-GlcNAc levels, thereby impacting global O-GlcNAcylation patterns. This model is particularly relevant for studying how hexosamine salvage contributes to cancer cell metabolism, drug resistance, and survival under nutrient stress, given that HeLa cells are frequently used in screens for metabolic inhibitors and chemotherapeutic agents.
Key research applications include dissecting the hexosamine biosynthetic pathway, characterizing O-GlcNAcylation dynamics, and evaluating metabolic vulnerabilities in cancer. The polyclonal knockout pool can be employed in assays such as Western blotting for protein O-GlcNAc, RT-qPCR for pathway gene expression, quantitative analysis of UDP-GlcNAc, lactate production measurements, and Seahorse-based metabolic flux profiling. Additional functional studies may encompass cell proliferation kinetics and Annexin V/PI apoptosis assays. This model supports both mechanistic investigations and high-throughput drug screening. For further details or to discuss specific experimental requirements, please contact Ascent Research.
